Valuation: OLIPASS Corporation

Market Cap 26.53B 19.47M 17.29M 16.17M 14.73M 27.74M 1.87B 28.12M 196M 75.72M 954M 73.08M 71.5M 3.07B P/E 2021
-10.8x
P/E 2022 -7.66x
Enterprise Value 20.34B 14.92M 13.25M 12.39M 11.29M 21.26M 1.44B 21.55M 150M 58.04M 732M 56.02M 54.8M 2.35B EV / Sales 2021
295x
EV / Sales 2022 79x
Free-Float
48.85%
Yield 2021 *
-
Yield 2022 -
3 years 1,568
Extreme 1568
33,500
5 years 1,568
Extreme 1568
115,000
10 years 1,568
Extreme 1568
240,666.67
Manager TitleAgeSince
Chief Executive Officer 54 22/05/2025
Corporate Officer/Principal 34 28/11/2024
Comptroller/Controller/Auditor 67 31/03/2025
Director TitleAgeSince
Director/Board Member 54 28/11/2024
Director/Board Member 34 28/11/2024
Director/Board Member 66 -
Change 5-day change 1-year change 3-year change Capi.($)
-13.92%-.--%-.--%-94.82% 9.88M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-2.77%+2.74%+29.40%+22.50% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -2.20%-5.06%+47.86%+129.34% 39.25B
Weighted average by Cap. -0.35%-0.32%+58.48%+146.08%

Financials

2021 2022
Net sales 852M 625K 555K 519K 473K 891K 60.17M 903K 6.28M 2.43M 30.64M 2.35M 2.3M 98.43M 2.3B 1.68M 1.5M 1.4M 1.28M 2.4M 162M 2.43M 16.93M 6.55M 82.6M 6.32M 6.19M 265M
Net income -25.13B -18.44M -16.38M -15.32M -13.96M -26.28M -1.78B -26.64M -185M -71.73M -904M -69.24M -67.74M -2.9B -24.17B -17.73M -15.75M -14.73M -13.42M -25.27M -1.71B -25.62M -178M -68.98M -869M -66.57M -65.13M -2.79B
Net Debt -18.29B -13.42M -11.92M -11.15M -10.16M -19.12M -1.29B -19.39M -135M -52.2M -658M -50.38M -49.29M -2.11B -6.2B -4.55M -4.04M -3.78M -3.44M -6.48M -438M -6.57M -45.67M -17.68M -223M -17.07M -16.7M -716M
Logo OLIPASS Corporation
OliPass Corp is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The Company is mainly engaged in the development of non-opioid analgesics, amyotrophic lateral sclerosis (ALS) treatments, therapies for age-related macular degeneration, and diabetic retinopathy. In addition, the Company researches, develops and sells functional cosmetics through artificial gene platform technology.
Employees
-
  1. Stock Market
  2. Stocks
  3. A244460 Stock